Real World Use, Effectiveness and Safety of Romosozumab among Osteoporosis Patients in Guangdong China (20250009)

Study identification

• EU PAS number:
  EUPAS1000000758
• Study ID:
  1000000758
• Official title and acronym:
  Real World Use, Effectiveness and Safety of Romosozumab among Osteoporosis Patients in Guangdong China (20250009)
• DARWIN EU® study:
  No
• Study countries:
  China
• Study description:
  No information provided.
• Study status:
  Planned

Study timelines

Date when funding contract was signed

Planned:28/02/2026

Study start date

Planned:01/04/2026

Data analysis start date

Planned:30/05/2026

Date of interim report, if expected

Planned:30/08/2026

Date of final study report

Planned:01/12/2026

Sources of funding

Pharmaceutical company and other private sector 

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable